FINWIRES · TerminalLIVE
FINWIRES

Market Chatter: Tiger to Bar China-Based Investors from Adding to Positions

By

Singapore-based Tiger Brokers will not allow its China-based investors to add to their positions when they are physically in mainland China, Reuters reported Tuesday, citing a notice to clients.

The brokerage said investors will still be allowed to trade their securities from existing accounts when they travel offshore, Reuters said.

The move comes after Chinese authorities informed Tiger and other brokers to wind down the accounts, which are illegal under Beijing's new rules on cross-border transactions, Reuters said.

China fined three brokerages in May for operating without proper approvals, among them Tiger Brokers (NZ), Futu Securities International (Hong Kong), and Changqiao Securities (Hong Kong), also known as Longbridge, according to a May 22 notice by the China Securities Regulatory Commission.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Related Articles

Asia

Jefferies Adjusts JX Advanced Metals' Price Target to 5,200 Yen From 4,300 Yen, Keeps at Buy

JX Advanced Metals (TYO:5016) has an average rating of overweight and mean price target of 4,370 yen, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$TYO:5016
Asia

Jefferies Adjusts Sungrow Power Supply's Price Target to 236.35 Yuan From 181.29 Yuan, Keeps at Buy

Sungrow Power Supply (SHE:300274) has an average rating of overweight and mean price target of 184.87 yuan, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$SHE:300274
Asia

Salubris Pharmaceuticals Unit Presents JK06's Clinical Trial Results At American Oncology Convention

Shenzhen Salubris Pharmaceuticals' (SHE:002294) unit, Salubris Biotherapeutics, presented the results of its clinical trial on the drug JK06 at the American Society of Clinical Oncology Annual Meeting, according to a Shenzhen bourse filing on Wednesday.The trials showed that the drug has safety and efficacy in patients with tumors, including non-small cell lung cancer and breast cancer.The trial enrolled 173 patients in Europe.Shares of the pharmaceutical company were down 2% at the close.

$SHE:002294